NeuroSense Therapeutics Ltd. Logo

NeuroSense Therapeutics Ltd.

A late-clinical stage company developing drugs for neurodegenerative diseases like ALS.

NRSN | US

Overview

Corporate Details

ISIN(s):
IL0011809592 (+1 more)
LEI:
Country:
United States of America
Address:
11 HAMENOFIM ST., 4672562 HERZLIYA

Description

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NeuroSense Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NeuroSense Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NeuroSense Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Entera Bio Ltd. Logo
A clinical-stage company developing oral peptide and protein replacement therapies.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Clinical-stage biopharma developing oral therapies for gastrointestinal diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Clinical-stage biopharma developing EEV-based therapies for rare diseases.
United States of America
TRDA
Develops small molecule therapeutics for cancer, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices for infections based on a proprietary marine enzyme technology.
Sweden
ENZY
Epitomee Medical Ltd. Logo
Develops ingestible therapeutic devices for chronic diseases.
Israel
EPIT
EQL Pharma AB Logo
Develops and sells niche generic and specialty medicines, primarily in Nordic markets.
Sweden
EQL
Erasca, Inc. Logo
A clinical-stage oncology company developing therapies for RAS/MAPK pathway-driven cancers.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Biopharmaceutical company developing cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Develops red blood cell-based therapies for cancer and orphan diseases.
France
ERYP

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.